More than three years after Pfizer (PFE) paid roughly $17 billion to acquire Hospira, the drug maker continues to encounter troubling manufacturing problems that are hobbling its ability to maximize the return on that investment.

The latest example occurred this month when Pfizer halted production at a plant in Sriperumbudur, India, after the U.S. Food and Drug Administration conducted an inspection last spring and subsequently issued a lengthy report that detailed a host of quality control issues.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy